GB0905641D0 - Compounds - Google Patents

Compounds

Info

Publication number
GB0905641D0
GB0905641D0 GBGB0905641.7A GB0905641A GB0905641D0 GB 0905641 D0 GB0905641 D0 GB 0905641D0 GB 0905641 A GB0905641 A GB 0905641A GB 0905641 D0 GB0905641 D0 GB 0905641D0
Authority
GB
United Kingdom
Prior art keywords
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB0905641.7A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Serodus AS
Original Assignee
Serodus AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Serodus AS filed Critical Serodus AS
Priority to GBGB0905641.7A priority Critical patent/GB0905641D0/en
Publication of GB0905641D0 publication Critical patent/GB0905641D0/en
Priority to CA2757106A priority patent/CA2757106A1/en
Priority to EP10712115A priority patent/EP2414331A1/en
Priority to MX2011010215A priority patent/MX2011010215A/en
Priority to JP2012502774A priority patent/JP2012522758A/en
Priority to US13/262,356 priority patent/US20120094989A1/en
Priority to PCT/GB2010/000656 priority patent/WO2010112865A1/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/34—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
GBGB0905641.7A 2009-04-01 2009-04-01 Compounds Ceased GB0905641D0 (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
GBGB0905641.7A GB0905641D0 (en) 2009-04-01 2009-04-01 Compounds
CA2757106A CA2757106A1 (en) 2009-04-01 2010-04-01 5-ht receptor modulating compounds
EP10712115A EP2414331A1 (en) 2009-04-01 2010-04-01 5-ht receptor modulating compounds
MX2011010215A MX2011010215A (en) 2009-04-01 2010-04-01 5-ht receptor modulating compounds.
JP2012502774A JP2012522758A (en) 2009-04-01 2010-04-01 5-HT receptor modulating compound
US13/262,356 US20120094989A1 (en) 2009-04-01 2010-04-01 5-ht receptor modulating compounds
PCT/GB2010/000656 WO2010112865A1 (en) 2009-04-01 2010-04-01 5-ht receptor modulating compounds

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0905641.7A GB0905641D0 (en) 2009-04-01 2009-04-01 Compounds

Publications (1)

Publication Number Publication Date
GB0905641D0 true GB0905641D0 (en) 2009-05-13

Family

ID=40672123

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB0905641.7A Ceased GB0905641D0 (en) 2009-04-01 2009-04-01 Compounds

Country Status (7)

Country Link
US (1) US20120094989A1 (en)
EP (1) EP2414331A1 (en)
JP (1) JP2012522758A (en)
CA (1) CA2757106A1 (en)
GB (1) GB0905641D0 (en)
MX (1) MX2011010215A (en)
WO (1) WO2010112865A1 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8563573B2 (en) 2007-11-02 2013-10-22 Vertex Pharmaceuticals Incorporated Azaindole derivatives as CFTR modulators
US8802868B2 (en) 2010-03-25 2014-08-12 Vertex Pharmaceuticals Incorporated Solid forms of (R)-1(2,2-difluorobenzo[D][1,3]dioxo1-5-yl)-N-(1-(2,3-dihydroxypropyl-6-fluoro-2-(1-hydroxy-2-methylpropan2-yl)-1H-Indol-5-yl)-Cyclopropanecarboxamide
CN103038214B (en) 2010-04-22 2015-09-30 弗特克斯药品有限公司 Prepare the method for cycloalkyl carboxamides base-benzazolyl compounds
PL3925607T3 (en) 2014-04-15 2023-10-30 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions for the treatment of cystic fibrosis transmembrane conductance regulator mediated diseases
KR102652797B1 (en) 2018-10-30 2024-04-02 길리애드 사이언시즈, 인코포레이티드 Compounds for inhibition of alpha4beta7 integrin
AU2019373245C1 (en) 2018-10-30 2022-10-27 Gilead Sciences, Inc. Compounds for inhibition of alpha 4β7 integrin
WO2020092394A1 (en) 2018-10-30 2020-05-07 Gilead Sciences, Inc. Imidazopyridine derivatives as alpha4beta7 integrin inhibitors
KR102630416B1 (en) 2018-10-30 2024-02-01 길리애드 사이언시즈, 인코포레이티드 Quinoline derivatives as alpha4beta7 integrin inhibitors
JP7491996B2 (en) 2019-08-14 2024-05-28 ギリアード サイエンシーズ， インコーポレイテッド Compounds for the inhibition of alpha4beta7 integrin
CN110950843B (en) * 2019-11-28 2022-12-27 广东东阳光药业有限公司 Substituted benzamide derivatives and uses thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5852014A (en) * 1992-03-12 1998-12-22 Smithkline Beecham P.L.C. Condensed indole derivatives as 5HT4 -receptor antagonists
US5998409A (en) * 1992-03-12 1999-12-07 Smithkline Beecham Plc Condensed indole derivatives as 5HT4 -receptor antagonists
ES2132223T3 (en) * 1992-03-12 1999-08-16 Smithkline Beecham Plc INDOL DERIVATIVES CONDENSED AS ANTAGONISTS OF THE 5-HT4 RECEPTOR.
WO1993024117A2 (en) * 1992-05-23 1993-12-09 Smithkline Beecham Plc Medicaments for the treatment of anxiety
ES2103675B1 (en) * 1995-01-10 1998-07-01 Almirall Lab NEW PIPERIDINES REPLACED.
DE602004025508D1 (en) * 2003-12-23 2010-03-25 Serodus As MODULATORS OF PERIPHERAL 5-HT RECEPTORS
EP1902044A1 (en) * 2005-07-07 2008-03-26 Bio Medisinsk Innovasjon AS 5-htx modulators
WO2007149929A1 (en) 2006-06-23 2007-12-27 Aryx Therapeutics, Inc. Piperidine derivatives for the treatment of gastrointestinal and cns disorders

Also Published As

Publication number Publication date
EP2414331A1 (en) 2012-02-08
MX2011010215A (en) 2012-02-28
US20120094989A1 (en) 2012-04-19
JP2012522758A (en) 2012-09-27
WO2010112865A1 (en) 2010-10-07
CA2757106A1 (en) 2010-10-07

Similar Documents

Publication Publication Date Title
GB0907425D0 (en) Compounds
EP2393493A4 (en) Compounds
GB0918249D0 (en) Compounds
EP2491025A4 (en) Azaazulene compounds
GB0907515D0 (en) Compounds
GB0914856D0 (en) Compounds
GB0915892D0 (en) Compounds
GB0919194D0 (en) Compounds
GB0905641D0 (en) Compounds
GB0909671D0 (en) Compounds
AP2909A (en) Pyrazinoisoquinoline Compounds
GB0915519D0 (en) Ntithrombotic compounds
GB0911000D0 (en) Compounds
GB0909672D0 (en) Compounds
EP2443115A4 (en) Compounds
GB0903948D0 (en) Compounds
GB0902796D0 (en) Compounds
GB0905057D0 (en) Compounds
GB0905060D0 (en) Compounds
GB0905932D0 (en) Compounds
GB0906378D0 (en) Compounds
GB0906433D0 (en) Compounds
GB0906853D0 (en) Compounds
GB0906854D0 (en) Compounds
GB0915789D0 (en) Compounds

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)